Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Dec 15;7(12):5310-6.
eCollection 2014.

The effect of captopril and losartan on the electrophysiology of myocardial cells of myocardial ischemia rats

Xiangmin Shi  1 , Zhaoling Shan  1 , Hongtao Yuan  1 , Hongyang Guo  1 , Yutang Wang  1
Affiliations

The effect of captopril and losartan on the electrophysiology of myocardial cells of myocardial ischemia rats

Xiangmin Shi et al. Int J Clin Exp Med. .

Abstract

Objective: This study aims to investigate the effect of captopril and losartan on the electrophysiology of myocardial cells parameters in ventricular vulnerable period and effective refractory period of myocardial ischemia rats.

Methods: 96 wistar rats were enrolled in the study and divided into six groups: Captopril myocardial ischemia group, losartan myocardial ischemia group, myocardial ischemia control group, captopril normal group, losartan normal group and normal control group (n=16). We observed morphological changes of myocardial tissue in each group. The cardiac electrophysiological parameters in effective refractory period of each group were measured. Creatine kinase (CK), alanine aminotransferase (GOT), lactate dehydrogenase (LDH), the expression of Cardiotrophin 1 (CT-1) and malonaldehyde (MDA) were detected.

Results: Compared the losartan and captopril group with the control group, (P<0.05). Losartan and captopril can shorten the ventricular vulnerable period of the normal group and ischemic group. There was no interaction effect between losartan and captopril group and the acute myocardial ischemia group. The effect of losartan and captopril on time window in ventricular vulnerable period showed that compared with the control group (P<0.05). Losartan and captopril had a significant effect on prolonged effective refractory period of normal and ischemic rats. There was no interaction effect between losartan and captopril group and the acute myocardial ischemia group. Compared with the myocardial ischemia control group, CK, GOT, LDH and MDA decreased in captopril and losartan myocardial ischemia groups (P<0.05).

Conclusion: Losartan and captopril had a significant effect on prolonged effective refractory period and shorten ventricular vulnerable period, they can also effectively prevent arrhythmias.

Keywords: Losartan; captopril; myocardial ischemia; rats.

PubMed Disclaimer

Figures

Figure 1
Figure 1
HE staining of myocardial tissue in different groups. A: Normal control group, B: Captopril normal group, C: Losartan normal group, D: Myocardial ischemia control group, E: Captopril myocardial ischemia group, F: Losartan myocardial ischemia group.
Figure 2
Figure 2
RT-PCR results of CT-1 expression levels in myocardial tissue in different groups. A: Normal control group, B: Captopril normal group, C: Losartan normal group, D: Myocardial ischemia control group, E: Captopril myocardial ischemia group, F: Losartan myocardial ischemia group.
Figure 3
Figure 3
MDA concentration in different groups. A: Normal control group, B: Captopril normal group, C: Losartan normal group, D: Myocardial ischemia control group, E: Captopril myocardial ischemia group, F: Losartan myocardial ischemia group. *P<0.05.
See this image and copyright information in PMC

References

    1. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau J, Shi VC, Solomon SD, Swedberg K, Zile MR PARADIGM-HF Committees and Investigators. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF) Eur J Heart Fail. 2013;15:1062–73. - PMC - PubMed
    1. Qian Q, Manning DM, Ou N, Klarich MJ, Leutink DJ, Loth AR, Lopez-Jimenez F. ACEi/ARB for systolic heart failure: closing the quality gap with a sustainable intervention at an academic medical center. J Hosp Med. 2011;6:156–160. - PubMed
    1. Warden BA, Freels JP, Furuno JP, Mackay J. Pharmacy-managed program for providing education and discharge instructions for patients with heart failure. Am J Health Syst Pharm. 2014;71:134–139. - PubMed
    1. Banka G, Heidenreich PA, Fonarow GC. Incremental cost-effectiveness of guideline-directed medical therapies for heart failure. Am Coll Cardiol. 2013;61:1440–1446. - PubMed
    1. Honjo T, Yamaoka-Tojo M, Inoue N. Pleiotropic effects of ARB in vascular metabolism--focusing on atherosclerosis-based cardiovascular disease. Curr Vasc Pharmacol. 2011;9:145–152. - PubMed

LinkOut - more resources